




- (51) International Patent Classification:
A61K 51/10 (2006.01)
- (21) International Application Number:
PCT/US2023/079693
- (22) International Filing Date:
14 November 2023 (14.11.2023)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/425,263 14 November 2022 (14.11.2022) US
- (71) Applicant: **AKTIS ONCOLOGY, INC.** [US/US]; 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 (US).
- (72) Inventors: **BLACKWELL III, William C.**; c/o AKTIS ONCOLOGY, INC., 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 (US). **SRIVASTAVA, Ved**; 517 Alliance Circle, Cary, North Carolina 27519 (US). **GOODMAN, Brian**; c/o AKTIS ONCOLOGY, INC.,

- 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 (US). **FELDMAN, Paul L.**; c/o AKTIS ONCOLOGY, INC., 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 (US). **WAY, James M.**; c/o AKTIS ONCOLOGY, INC., 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 (US). **KOVACS, Jeff**; c/o AKTIS ONCOLOGY, INC., 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 (US). **KIL, Hyun Joo**; 1325 Dominion Oak Circle, Cary, North Carolina 27519 (US). **GOBER, Isaiah Nathaniel**; c/o AKTIS ONCOLOGY, INC., 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 (US). **DOLIGALSKI, Michael Lawrence**; c/o AKTIS ONCOLOGY, INC., 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 (US). **KOSCIUK, Tatsiana**; c/o AKTIS ONCOLOGY, INC., 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210 (US).
- (74) Agent: **ZHANG, Clark et al.**; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

(54) Title: DECREASED RETENTION OF MINIPROTEINS IN KIDNEY

FIG. 1



(57) Abstract: Provided herein are compositions and methods of treating, diagnosing, monitoring, and/or imaging a disease, disorder, or condition using radiopharmaceuticals selective for various targets. More specifically, compositions and methods disclosed herein decrease kidney retention or potential reuptake in the kidney where the targets are expressed in the kidney. Various approaches are disclosed to mitigate kidney retention of radiopharmaceuticals.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*